SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Cardiff Oncology (CRDF) Reports $30.4M Net Loss; Phase 3 Start Expected in Q1 2027

Cardiff Oncology reported a $30.4M net loss for the nine months ended September 30, 2026, versus $38.6M a year earlier. Median PFS was not reached in the 30 mg onvansertib arm versus approximately 11 months in combined standard-of-care arms; Phase 3 may start in Q1 2027, subject to additional finan…

CRDF

Related stories